OSU-6162 HYDROCHLORIDE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H23NO2S.ClH
Molecular Weight	317.875
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCCN1CCC[C@H](C1)C2=CC(=CC=C2)S(C)(=O)=O

InChI

InChIKey=LEMGVHZVBREXAD-PFEQFJNWSA-N

InChI=1S/C15H23NO2S.ClH/c1-3-9-16-10-5-7-14(12-16)13-6-4-8-15(11-13)19(2,17)18;/h4,6,8,11,14H,3,5,7,9-10,12H2,1-2H3;1H/t14-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C15H23NO2S
Molecular Weight	281.414
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27120292 | https://www.ncbi.nlm.nih.gov/pubmed/11312565 | https://www.ncbi.nlm.nih.gov/pubmed/21866391

PNU-96391A (known as OSU6162) is a weak dopamine (DA) D(2) receptor antagonist with behavioral stabilizing properties. OSU6162 seem to act as stabilizers not only on dopaminergic, but also on serotonergic brain signaling (partial agonist on 5-HT2A receptor). OSU6162 in a phase II European clinical trial in treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. One of the isomer of OSU 6162, has promise for treating Parkinson's disease, Huntington's disease and schizophrenia, but both enantiomers of OSU 6162 had dual effects on behavior, stimulating locomotor activity in 'low activity' animals and inhibiting locomotor activity in 'high activity' animals.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 311 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11312565	Modulator 846		447.0 nM [Ki]
Serotonin 2a (5-HT2a) receptor 237 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21874578	Modulator 846

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic Fatigue Syndrome 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27120292	Primary		Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
0.245 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	N-DEPROPYL-(-)-OSU 6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.543 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	N-DEPROPYL-(-)-OSU 6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.0178 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	N-DEPROPYL-(-)-OSU 6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.1 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	N-DEPROPYL-(-)-OSU 6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.19 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	OSU-6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.2 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	OSU-6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.038 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OSU-6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.372 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OSU-6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
2.27 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	N-DEPROPYL-(-)-OSU 6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.18 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	N-DEPROPYL-(-)-OSU 6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.24 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	N-DEPROPYL-(-)-OSU 6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.53 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	N-DEPROPYL-(-)-OSU 6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
14.8 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	OSU-6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.87 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	OSU-6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.223 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OSU-6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.69 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OSU-6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
5.89 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	N-DEPROPYL-(-)-OSU 6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.32 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	N-DEPROPYL-(-)-OSU 6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.94 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	N-DEPROPYL-(-)-OSU 6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.37 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	N-DEPROPYL-(-)-OSU 6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	OSU-6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	OSU-6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.77 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OSU-6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.33 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14973308/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OSU-6162 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
45 mg 2 times / day multiple, oral Highest studied dose Dose: 45 mg, 2 times / day Route: oral Route: multiple Dose: 45 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30132786	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/30132786	Other AEs: Fatigue, Headache... Other AEs: Fatigue (3.6%) Headache (7.1%) Nasopharyngitis (3.6%) Sources: https://pubmed.ncbi.nlm.nih.gov/30132786

AEs

AE	Significance	Dose	Population
Fatigue	3.6%	45 mg 2 times / day multiple, oral Highest studied dose Dose: 45 mg, 2 times / day Route: oral Route: multiple Dose: 45 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30132786	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/30132786
Nasopharyngitis	3.6%	45 mg 2 times / day multiple, oral Highest studied dose Dose: 45 mg, 2 times / day Route: oral Route: multiple Dose: 45 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30132786	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/30132786
Headache	7.1%	45 mg 2 times / day multiple, oral Highest studied dose Dose: 45 mg, 2 times / day Route: oral Route: multiple Dose: 45 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30132786	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/30132786

Sourcing

Vendor/Aggregator	ID	URL
Alfa Chemistry	9297	http://www.alfa-chemistry.com/search.aspx?q=9297
Alfa Chemistry	AFI156907845	http://www.alfa-chemistry.com/search.aspx?q=AFI156907845
Angene	AGN-PC-0O3DIT	http://www.angenechemical.com/productshow/AGN-PC-0O3DIT.html
BioSynth	J-501275	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/J-501275
BOC Sciences	146798-66-5	http://www.bocsci.com/description.asp?cas=146798-66-5
BOC Sciences	156907-84-5	http://www.bocsci.com/description.asp?cas=156907-84-5
eMolecules	31591103	https://orderbb.emolecules.com/search/#?query=31591103
eMolecules	36500597	https://orderbb.emolecules.com/search/#?query=36500597
eMolecules	48542828	https://orderbb.emolecules.com/search/#?query=48542828
mcule	MCULE-1147545508	https://mcule.com/MCULE-1147545508/
mcule	MCULE-5862763060	https://mcule.com/MCULE-5862763060/
MolPort	MolPort-023-276-502	https://www.molport.com/shop/molecule-link/MolPort-023-276-502
MuseChem	I010589	https://www.musechem.com/product/I010589.html
MuseChem	R006458	https://www.musechem.com/product/R006458.html
MuseChem	R012240	https://www.musechem.com/product/R012240.html
Tocris	2599	https://www.tocris.com/search.php?Type=QuickSearch&Value=2599
Toronto Research Chemicals	O006162	https://www.trc-canada.com/product-detail/?CatNum=O006162
Wonderchem	WD0582Z	http://www.wonder-chem.com/search.html?text=WD0582Z
Wonderchem	WD05AG4	http://www.wonder-chem.com/search.html?text=WD05AG4

PubMed

Title	Date	PubMed
The Effects of (-)-OSU6162 on Chronic Fatigue in Patients With Traumatic Brain Injury: A Randomized Controlled Trial.	2016-04-28	27120292
II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.	2011-11	21866391
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat.	2006-08	16648369
Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.	2001-05	11312565

Patents

Sample Use Guides

In Vivo Use Guide

OSU6162 of 30-60 mg/day

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:59:35 GMT 2025` Edited by `admin` on `Mon Mar 31 17:59:35 GMT 2025`
Record UNII	V5SBJBUJW6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OSU-6162 HYDROCHLORIDE

Code

English

3-(3-METHANESULFONYL-PHENYL)-1-PROPYL-PIPERIDINE HYDROCHLORIDE

Preferred Name

English

PIPERIDINE, 3-(3-(METHYLSULFONYL)PHENYL)-1-PROPYL-, HYDROCHLORIDE, (S)-

Systematic Name

English

Classification Tree Code System Code

EU-Orphan Drug

3-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine hydrochloride